Quantcast
Search Daily Dose & Film Annex
Loading

BIO SmartBrief

Daily Dose Newsletter

Tuesday
May152012

Speakers/Companies Added - "Cancer Immunotherapy: A Long-Awaited Reality" Conference

New speakers and presenting companies have been added to the list for the 3rd Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference.

This conference, which is being held on Thursday, October 4, 2012, at the New York Academy of Medicine, is a unique, single-day conference event uniting "founding visionary researchers, clinicians, business leaders, key investors, and other stakeholders to engage in discussions, exchange information, highlight opportunities, and showcase leading companies in the field of cancer immunotherapy."
 
Partial list of presenting companies (as of May 15):
  • Agenus Inc. (AGEN) 
  • Bavarian Nordic (BAVA.CO) 
  • DCPrime (private) 
  • Dendreon Corporation (DNDN) 
  • Formula Pharmaceuticals (private) 
  • Galena Biopharma (GALE) 
  • GlobeImmune (private) 
  • HEAT Biologics (private) 
  • Idera Pharmaceuticals, Inc. (IDRA) 
  • OncoSec Medical Incorporated (ONCS)
Partial list of speakers (as of May 15):
  • Charles C. Duncan, Ph.D., JMP Securities LLC 
  • James Gulley, M.D., Ph.D., F.A.C.P., National Cancer Institute 
  • Reiner Laus, M.D., Bavarian Nordic 
  • Joseph Pantginis, Ph.D., ROTH Capital Partners 
  • Andrew T. Parsa, M.D., Ph.D., University of California, San Francisco 
  • Col. George E. Peoples, M.D., F.A.C.S., Brooke Army Medical Center 
  • David Sable, M.D., Special Situations Life Sciences Fund 
  • Susan Slovin, M.D., Ph.D., F.A.C.P., Memorial Sloan-Kettering Cancer Center
  • Jedd D. Wolchok, M.D., Ph.D., Associate Attending Physician at Memorial Sloan-Kettering Cancer Center (MSKCC) and Associate Director of the Ludwig Center for Cancer Immunotherapy, as well as Director of Immunotherapy Clinical Trials
For individual registration and/or company presentation slots, and for more information, please click on the conference website link below:

PrintView Printer Friendly Version

EmailEmail Article to Friend

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

PostPost a New Comment

Enter your information below to add a new comment.

My response is on my own website »
Author Email (optional):
Author URL (optional):
Post:
 
Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>
« ACH-3102 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C (ACHN) | Main | Panel backs Gilead Sciences' Truvada for HIV-1 prophylaxis (GILD) »